Table 2 Comorbid diseases at baseline and the end of follow-up period
| Baseline | End of follow-up | |||||
|---|---|---|---|---|---|---|
| NAFLD | AFLD | p-value | NAFLD | AFLD | p-value | |
| n = 151 | n = 94 | n = 151 | n = 94 | |||
| n (%) | n (%) | n (%) | n (%) | |||
| DM II | 22 (15) | 8 (9) | NS | 42 (28) | 16 (17) | NS |
| HTN | 53 (35) | 37 (39) | NS | 79 (52) | 44 (47) | NS |
| Hyperlipidemia | 28 (19) | 12 (13) | NS | 32 (21) | 16 (17) | NS |
| Cardio- and cerebrovascular disease | 19 (13) | 11 (11) | NS | 44 (29) | 24 (26) | NS |